PE20211742A1 - Anticuerpos agonistas de cd200r y sus usos - Google Patents
Anticuerpos agonistas de cd200r y sus usosInfo
- Publication number
- PE20211742A1 PE20211742A1 PE2021000243A PE2021000243A PE20211742A1 PE 20211742 A1 PE20211742 A1 PE 20211742A1 PE 2021000243 A PE2021000243 A PE 2021000243A PE 2021000243 A PE2021000243 A PE 2021000243A PE 20211742 A1 PE20211742 A1 PE 20211742A1
- Authority
- PE
- Peru
- Prior art keywords
- comprises seq
- cd200r
- antibodies
- seq
- agonist
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862731204P | 2018-09-14 | 2018-09-14 | |
| PCT/US2019/050511 WO2020055943A1 (en) | 2018-09-14 | 2019-09-11 | Cd200r agonist antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20211742A1 true PE20211742A1 (es) | 2021-09-06 |
Family
ID=68051977
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2021000243A PE20211742A1 (es) | 2018-09-14 | 2019-09-11 | Anticuerpos agonistas de cd200r y sus usos |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US11319370B2 (enExample) |
| EP (1) | EP3849667A1 (enExample) |
| JP (3) | JP7185051B2 (enExample) |
| KR (1) | KR102705378B1 (enExample) |
| CN (2) | CN118530360A (enExample) |
| AR (1) | AR116668A1 (enExample) |
| AU (1) | AU2019339334B2 (enExample) |
| BR (1) | BR112021003254A2 (enExample) |
| CA (1) | CA3112763C (enExample) |
| CL (1) | CL2021000606A1 (enExample) |
| CO (1) | CO2021003093A2 (enExample) |
| CR (1) | CR20210134A (enExample) |
| DO (1) | DOP2021000040A (enExample) |
| EA (1) | EA202190530A1 (enExample) |
| EC (1) | ECSP21017619A (enExample) |
| IL (1) | IL281442B2 (enExample) |
| JO (1) | JOP20210048B1 (enExample) |
| MA (1) | MA53604A (enExample) |
| MX (1) | MX2021003026A (enExample) |
| MY (1) | MY196156A (enExample) |
| NZ (1) | NZ773626A (enExample) |
| PE (1) | PE20211742A1 (enExample) |
| PH (1) | PH12021550530A1 (enExample) |
| SG (1) | SG11202101697YA (enExample) |
| TW (1) | TWI749367B (enExample) |
| WO (1) | WO2020055943A1 (enExample) |
| ZA (2) | ZA202101246B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4045641A1 (en) | 2019-10-15 | 2022-08-24 | Eli Lilly and Company | Recombinantly engineered, lipase/esterase-deficient mammalian cell lines |
| WO2021243204A1 (en) * | 2020-05-29 | 2021-12-02 | 23Andme, Inc. | Anti-cd200r1 antibodies and methods of use thereof |
| AU2023251091A1 (en) * | 2022-04-06 | 2024-10-10 | Gilead Sciences, Inc. | Engineered cd200r antibodies and uses thereof |
| CN115458048B (zh) * | 2022-09-16 | 2023-05-26 | 杭州美赛生物医药科技有限公司 | 基于序列编解码的抗体人源化方法 |
| IL325073A (en) | 2023-06-02 | 2026-02-01 | Aimed Bio Inc | Anti-CD200R1 antibody and its uses |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7368535B2 (en) * | 2001-05-24 | 2008-05-06 | Trillium Therapeutics Inc. | CD200 receptors |
| DK1482973T3 (da) * | 2002-03-15 | 2009-12-07 | Schering Corp | Fremgangsmåde til modulering af CD200-receptorer |
| US8075884B2 (en) * | 2006-01-12 | 2011-12-13 | Alexion Pharmaceuticals, Inc. | Antibodies to OX-2/CD200 and uses thereof |
| KR20090094846A (ko) * | 2006-12-22 | 2009-09-08 | 쉐링 코포레이션 | Ｃｄ200ｒ에 대한 항체 |
| JP6012473B2 (ja) * | 2010-01-11 | 2016-10-25 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 抗ｃｄ２００抗体を用いたヒトの処置における免疫調節効果のバイオマーカー |
| BR112012020101A2 (pt) * | 2010-02-11 | 2018-09-25 | Alexion Pharma Inc | método diagnósticos e terapêuticos usando anticorpos anti-cd200. |
| WO2015057906A1 (en) | 2013-10-16 | 2015-04-23 | Janssen Biotech, Inc. | Cd200 receptor 1 agonists |
-
2019
- 2019-09-10 AR ARP190102571A patent/AR116668A1/es unknown
- 2019-09-10 TW TW108132514A patent/TWI749367B/zh active
- 2019-09-11 US US16/567,256 patent/US11319370B2/en active Active
- 2019-09-11 BR BR112021003254-1A patent/BR112021003254A2/pt unknown
- 2019-09-11 CN CN202410652453.6A patent/CN118530360A/zh not_active Withdrawn
- 2019-09-11 NZ NZ773626A patent/NZ773626A/en not_active IP Right Cessation
- 2019-09-11 PE PE2021000243A patent/PE20211742A1/es unknown
- 2019-09-11 MY MYPI2021001321A patent/MY196156A/en unknown
- 2019-09-11 CN CN201980060272.1A patent/CN112739422B/zh active Active
- 2019-09-11 WO PCT/US2019/050511 patent/WO2020055943A1/en not_active Ceased
- 2019-09-11 MX MX2021003026A patent/MX2021003026A/es unknown
- 2019-09-11 CR CR20210134A patent/CR20210134A/es unknown
- 2019-09-11 EA EA202190530A patent/EA202190530A1/ru unknown
- 2019-09-11 SG SG11202101697YA patent/SG11202101697YA/en unknown
- 2019-09-11 AU AU2019339334A patent/AU2019339334B2/en active Active
- 2019-09-11 JP JP2021538177A patent/JP7185051B2/ja active Active
- 2019-09-11 EP EP19773670.5A patent/EP3849667A1/en active Pending
- 2019-09-11 KR KR1020217007520A patent/KR102705378B1/ko active Active
- 2019-09-11 CA CA3112763A patent/CA3112763C/en active Active
- 2019-09-11 IL IL281442A patent/IL281442B2/en unknown
- 2019-09-11 MA MA053604A patent/MA53604A/fr unknown
-
2021
- 2021-02-24 ZA ZA2021/01246A patent/ZA202101246B/en unknown
- 2021-03-02 DO DO2021000040A patent/DOP2021000040A/es unknown
- 2021-03-09 CO CONC2021/0003093A patent/CO2021003093A2/es unknown
- 2021-03-11 JO JOJO/P/2021/0048A patent/JOP20210048B1/ar active
- 2021-03-11 PH PH12021550530A patent/PH12021550530A1/en unknown
- 2021-03-11 CL CL2021000606A patent/CL2021000606A1/es unknown
- 2021-03-12 EC ECSENADI202117619A patent/ECSP21017619A/es unknown
-
2022
- 2022-04-21 US US17/726,262 patent/US20220251198A1/en not_active Abandoned
- 2022-05-06 ZA ZA2022/04978A patent/ZA202204978B/en unknown
- 2022-07-28 JP JP2022120801A patent/JP7490025B2/ja active Active
-
2024
- 2024-05-14 JP JP2024078485A patent/JP2024105529A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR126242A2 (es) | Tratamiento del cáncer utilizando receptores de antígenos quiméricos | |
| AR110017A1 (es) | Anticuerpos de pd-1 y usos de estos | |
| AR065420A1 (es) | Anticuerpos anti-il-23 p19 de ingenieria | |
| PE20110225A1 (es) | Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5 | |
| AR103713A1 (es) | Anticuerpos contra tau y sus usos | |
| EA201591113A1 (ru) | Антитела против антигена 2 дендритных клеток крови и их применение | |
| EA035160B9 (ru) | Антитела к st2 и их применение | |
| PE20200011A1 (es) | ANTICUERPOS ANTI-PEPTIDO BETA AMILOIDE N3pGlu Y SUS USOS | |
| MX2021011167A (es) | Anticuerpos humanizados anti grupo de diferenciacion 19 (cd19) humano y metodos de uso. | |
| PE20130817A1 (es) | Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos | |
| PE20200294A1 (es) | Anticuerpos que se unen especificamente a pd-1 y metodos de uso | |
| PE20181089A1 (es) | Anticuerpos anti-cd19 humano con alta afinidad | |
| AR106184A1 (es) | Proteínas de unión a pd-1 y sus métodos de uso | |
| HRP20192098T1 (hr) | Antitijela na glukokortikoidom inducirani receptor faktora nekroze tumora (gitr) i njihove primjene | |
| MX2019007848A (es) | Anticuerpos anti-pd-1 y usos de los mismos. | |
| CO6230999A2 (es) | Anticuerpo anti-esclerostina | |
| PE20091382A1 (es) | Anticuerpos que se une a il-4 y/o a il-13 | |
| CR20190009A (es) | Anticuerpos anti-pd-1, un método de producción y un método para su uso. | |
| MX2018009524A (es) | Composiciones del polipeptido de fusion tnfr: fc exentas de arginina y metodos de uso. | |
| ES2687282T3 (es) | Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos | |
| PE20141166A1 (es) | Anticuerpos anti-angptl3 y usos de los mismos | |
| AR111830A1 (es) | Anticuerpos monoclonales antagonistas contra cd40 y sus usos | |
| PE20090161A1 (es) | Anticuerpos monoclonales anti cxcl13 | |
| AR082518A1 (es) | Anticuerpos contra il-18r1 y usos de los mismos | |
| AR104906A1 (es) | Anticuerpos dirigidos a la proteína morfogenética ósea 9 (bmp9) y métodos a partir de estos |